Anti-Hyperuricemic and Nephroprotective Effects of Rhein in Hyperuricemic Mice

 

 Buy Article Permissions and Reprints

Abstract

Hyperuricemia has been considered to be a key risk factor for kidney disease. The formation of uric acid crystals in the kidney further stimulates an intensive inflammatory response. Rhein possesses various pharmacological activities, including anti-inflammatory, antioxidative, antitumor, purgative effects, and so on. To our knowledge, no previous work has been reported about the therapeutic effect of rhein on urate nephropathy. In this study, a model of hyperuricemia and nephropathy induced by adenine and ethambutol in mice was established. Meanwhile, the potential beneficial effects and mechanisms of rhein on hyperuricemia and nephropathy were also investigated. The results demonstrated that rhein significantly decreased the serum uric acid level by inhibiting the xanthine oxidase activity and increasing the excretion of urinary uric acid. In addition, rhein also markedly improved kidney damage related to hyperuricemia. Further investigation indicated that rhein improved the symptoms of nephropathy through decreasing the production of proinflammatory cytokines, including interleukin 1β, prostaglandin E₂, and tumor necrosis factor-α and inhibiting the expression of transforming growth factor-β1. The present study suggests that rhein may have a considerable potential for development as an anti-hyperuricemic and nephroprotective agent for clinical application.

• References

• 1 Wortmann R. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14: 281-286
  CrossrefPubMedGoogle Scholar
• 2 Feig D, Rodriguez-Iturbe B, Nakagawa T, Johnson R. Nephron number, uric acid, and renal microvascular disease in the pathogenesis of essential hypertension. Hypertension 2006; 48: 25-26
  CrossrefPubMedGoogle Scholar
• 3 Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241
  CrossrefPubMedGoogle Scholar
• 4 Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004; 64: 2399-2416
  CrossrefPubMedGoogle Scholar
• 5 Chen I, Kuo M, Hwang S, Chang J, Chen H. Allopurinol-induced severe hypersensitivity with acute renal failure. Kaohsiung J Med Sci 2005; 21: 228-232
  CrossrefPubMedGoogle Scholar
• 6 Horiuchi H, Ota M, Nishimura S, Kaneko H, Kasahara Y, Ohta T, Komoriya K. Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. Life Sci 2000; 66: 2051-2070
  CrossrefPubMedGoogle Scholar
• 7 Mari E, Ricci F, Imberti D, Gallerani M. Agranulocytosis: an adverse effect of allopurinol treatment. Ital J Med 2011; 5: 120-123
  CrossrefPubMedGoogle Scholar
• 8 Wu X, Liu L, Xie H, Liao J, Zhou X, Wan J, Yu K, Li J, Zhang Y. Tanshinone IIA prevents uric acid nephropathy in rats through NF-κB inhibition. Planta Med 2012; 78: 866-873
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Chen L, Lan Z, Zhou Y, Li F, Zhang X, Zhang C, Yang Z, Li P. Astilbin attenuates hyperuricemia and ameliorates nephropathy in fructose-induced hyperuricemic rats. Planta Med 2011; 77: 1769-1773
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Shi Y, Wang C, Wang X, Zhang Y, Liu L, Wang R, Ye J, Hu L, Kong L. Uricosuric and nephroprotective properties of Ramulus Mori ethanol extract in hyperuricemic mice. J Ethnopharmacol 2012; 143: 896-904
  CrossrefPubMedGoogle Scholar
• 11 Hou S, Zhu W, Pang M, Jeffry J, Zhou L. Protective effect of iridoid glycosides from Paederia scandens (LOUR.) MERRILL (Rubiaceae) on uric acid nephropathy rats induced by yeast and potassium oxonate. Food Chem Toxicol 2014; 64: 57-64
  CrossrefPubMedGoogle Scholar
• 12 Chen L, Lan Z, Lin Q, Mi X, He Y, Wei L, Lin Y, Zhang Y, Deng X. Polydatin ameliorates renal injury by attenuating oxidative stress-related inflammatory responses in fructose-induced urate nephropathic mice. Food Chem Toxicol 2013; 52: 28-35
  CrossrefPubMedGoogle Scholar
• 13 State Administration of Traditional Chinese Medicine of Peopleʼs Republic of China. Zhong-hua-ben-cao. Shanghai: Shanghai Science and Technology Publisher; 1999: 708-721
  Google Scholar
• 14 Legendre F, Heuze A, Boukerrouche K, Leclercq S, Boumediene K, Galera P, Domagala F, Pujol J, Ficheux H. Rhein, the metabolite of diacerhein, reduces the proliferation of osteoarthritic chondrocytes and synoviocytes without inducing apoptosis. Scand J Rheumatol 2009; 38: 104-111
  CrossrefPubMedGoogle Scholar
• 15 Huang S, Yeh S, Hong C. Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria: structure-activity relationship. J Nat Prod 1995; 58: 1365-1371
  CrossrefPubMedGoogle Scholar
• 16 Hsia T, Yang J, Chen G, Chiu T, Lu H, Yang M, Yu F, Liu K, Lai K, Lin C, Chung J. The roles of endoplasmic reticulum stress and Ca²⁺ on rhein-induced apoptosis in A-549 human lung cancer cells. Anticancer Res 2009; 29: 309-318
  PubMedGoogle Scholar
• 17 Zhang W, Li F, Bao J, Wang S, Shang G, Li JC, Wang C. Regulative effects of aquaporin 4 expression by rhein in rhubarb to intestinal epithelial cell line LoVo. Zhong Yao Cai 2008; 31: 702-706
  PubMedGoogle Scholar
• 18 Gao Q, Qin W, Jia Z, Zheng J, Zeng C, Li L, Liu Z. Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy. Planta Med 2010; 76: 27-33
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 He D, Lee L, Yang J, Wang X. Preventive effects and mechanisms of rhein on renal interstitial fibrosis in obstructive nephropathy. Biol Pharm Bull 2011; 34: 1219-1226
  CrossrefPubMedGoogle Scholar
• 20 Gibson T. Hyperuricemia, gout and the kidney. Curr Opin Rheumatol 2012; 24: 127-131
  CrossrefPubMedGoogle Scholar
• 21 Pillinger M, Rosenthal P, Abeles A. Hyperuricemia and gout: new insights into pathogenesis and treatment. Bull NYU Hosp Jt Dis 2007; 65: 215-221
  PubMedGoogle Scholar
• 22 So A. Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008; 10: 221
  CrossrefPubMedGoogle Scholar
• 23 Roncal C, Mu W, Croker B, Reungjui S, Ouyang X, Tabah-Fisch I, Johnson R, Ejaz A. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2007; 292: 116-122
  PubMedGoogle Scholar
• 24 Philips F, Thiersch J, Bendich A. Adenine intoxication in relation to in vivo formation and deposition of 2, 8-dioxya-denine in renal tubules. J Pharmacol Exp Ther 1952; 104: 20-30
  PubMedGoogle Scholar
• 25 Hu Q, Miao M, Lu G, Ji H. Effects of quercetin on expression of renal NLRP3 and TLRs in rats with uric acid nephropathy. Zhong Cao Yao 2013; 44: 3496-3502
  PubMedGoogle Scholar
• 26 Liu J, Xu L, Xu Y. Anti-gout active fractions in Tongfeng Granule. Zhong Cao Yao 2013; 44: 590-594
  PubMedGoogle Scholar
• 27 Sorbera L, Sharanya S, Dulsat C, Rosa E. Therapeutic targets for gout. Drugs Future 2010; 5: 333-337
  PubMedGoogle Scholar
• 28 Chen C, Shi Y, Hearn A, Fitzgerald K, Golenbock D, Reed G, Akira S, Rock K. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006; 116: 2262-2271
  CrossrefPubMedGoogle Scholar
• 29 Guan Z, Buckman S, Miller B, Springer L, Morrison A. Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p 38 MAPK signal pathways in rat renal mesangial cells. J Biol Chem 1998; 273: 28670-28676
  CrossrefPubMedGoogle Scholar
• 30 Beyaert R, Fiers W. Tumor Necrosis Factor and lymphotoxin. In: Mire-Sluis AR, Thorpe R, editors Cytokines. San Diego: Academic Press; 1998: 335-359
  CrossrefGoogle Scholar
• 31 Nakanishi M, Rosenberg D. Multifaceted roles of PGE₂ in inflammation and cancer. Semin Immunopathol 2013; 35: 123-137
  CrossrefPubMedGoogle Scholar
• 32 Eddy A. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508
  PubMedGoogle Scholar
• 33 Border W, Noble N. Transforming growth factor beta tissue fibrosis. N Engl J Med 1994; 331: 1286-1292
  CrossrefPubMedGoogle Scholar
• 34 Hu Y, Ye S, Zhao L, Zheng M, Chen Y. Hydrochloride pioglitazone decreases urinary TGF-β1 excretion in type 2 diabetics. Eur J Clin Invest 2010; 40: 571-574
  CrossrefPubMedGoogle Scholar
• 35 Chen G, Xu S. Research progress for animal hyperuricemia model. Chin Pharm Bull 2004; 20: 369-373
  PubMedGoogle Scholar
• 36 Guo C, Han F, Zhang C, Xiao W, Yang Z. Protective effects of oxymatrine on experimental diabetic nephropathy. Planta Med 2014; 80: 269-276
  Article in Thieme ConnectPubMedGoogle Scholar
• 37 Mo S, Zhou F, Lv Y, Hu Q, Zhang D, Kong L. Hypouricemic action of selected flavonoids in mice: structure-activity relationships. Biol Pharm Bull 2007; 30: 1551-1556
  CrossrefPubMedGoogle Scholar
• 38 Lowry O, Rosebrough N, Farr A, Randall R. Protein measurement with folin-phenol reagent. J Biol Chem 1951; 193: 265-275
  PubMedGoogle Scholar

• Supplementary Material